This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Apellis Pharmaceuticals’s 8K filing here.
About Apellis Pharmaceuticals
Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).
Further Reading
- Five stocks we like better than Apellis Pharmaceuticals
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Rigetti Computing, Inc.: Buy, Sell, or Hold for 2025
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Delta Can Fly to New Highs in 2025; Here’s Why
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Snowflake Stock: Bullish Upgrades Demand Investors’ Attention
